Massive Bio and Mika Health, two leading AI-enabled healthcare technology companies, announced a partnership aimed at enhancing access to clinical trials, biomarker testing, and digital therapeutics for cancer patients.
The collaboration will allow patients receiving treatment through Mika Health's personalized oncology digital therapeutic platform to opt into Massive Bio's AI-powered clinical trial matching system and next-generation sequencing (NGS) biomarker testing eligibility engine. Conversely, Massive Bio will provide free access to Mika Health's digital therapy to its registry of hundreds of thousands of cancer patients.
"Patients waiting to find and access effective cancer treatments face tremendous challenges, both physical and mental," said Dr. Gandolf Finke, CEO and Found
Massive Bio, Mika Health Blend AI with Digital Therapy to Boost Cancer Trial Access
- By Abhijeet Adhikari
- Published on
The partnership aims to streamline clinical trial enrollment, reduce manual effort, and ultimately improve treatment options and outcomes through data-driven insights into patient experiences and real-world evidence.
